BriaCell Highlights Potent Preclinical Anti‑Cancer Activity For Next‑Gen Bria‑OTS+ Platform
BriaCell Therapeutics (NASDAQ: BCTX) presented new preclinical data showing that its next‑generation Bria‑OTS+ off‑the‑shelf immunotherapy platform triggers strong, coordinated immune responses and robust tumor‑killing activity across multiple cancer models. The data were shared in a poster focused on Bria‑OTS+ and its lead candidates, Bria‑BRES+ for breast cancer and Bria‑PROS+ for prostate cancer.
How Bria‑OTS+ works in models
The company reported that Bria‑OTS+ activates both arms of the immune system—innate and adaptive—leading to broad anti‑tumor effects. In preclinical studies, Bria‑BRES+ and Bria‑PROS+ rapidly engaged CD4/CD8 T cells, NK/NKT cells and B cells, increased cytokine release, and produced durable anti‑cancer immune responses without signs of immune exhaustion, a key driver of cancer progression.
Platform breadth and lead programs
BriaCell emphasized that Bria‑OTS+ was designed as an enhanced version of its original Bria‑OTS platform, engineered to express multiple immune‑activating cytokines and co‑stimulatory molecules to deepen immune engagement. The new data suggest activity not just in breast and prostate cancer models, but also in additional solid tumor types such as lung cancer and melanoma that share similar immune‑recognition features.
Next steps toward the clinic
Bria‑BRES+ and Bria‑PROS+ have completed GMP manufacturing and are slated for evaluation in upcoming Phase 1/2a clinical studies, with Bria‑PROS+ supported by a 2 million NCI SBIR grant. These programs will run in parallel with BriaCell’s pivotal Phase 3 trial of its Bria‑IMT plus checkpoint inhibitor regimen in metastatic breast cancer (NCT06072612), which has already shown encouraging quality‑of‑life and safety data.
Investor perspective
For investors, the Bria‑OTS+ update reinforces BriaCell’s positioning as an early‑stage platform immunotherapy story with multiple shots on goal in breast, prostate and other solid tumors. The preclinical data are promising but non‑pivotal; the real value inflection will depend on whether Bria‑BRES+ and Bria‑PROS+ can reproduce this rapid, durable immune activation in humans and slot into a crowded immuno‑oncology landscape alongside players like Bristol Myers Squibb (BMY) and Merck (MRK).
